Altre lingue Sangamo Therapeutics, Inc.

Azioni

SGMO

US8006771062

Tempo reale stimato Cboe BZX Altri mercati azionari 18:39:48 24/04/2024			Variaz. 5gg	Var. 1 gen.
0,493 ^USD	-5,36%		-4,28%	-9,09%

22/03	Sangamo Therapeutics prezza un'offerta diretta registrata da 24 milioni di dollari	MT
14/03	Sangamo Therapeutics spinge i programmi neurologici verso lo sviluppo clinico, dice Wedbush	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data from Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting	23/04
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)	22/04
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering	25/03
Sangamo Therapeutics Prices $24 Million Registered Direct Offering	22/03
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering	22/03
Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says	14/03
Sangamo: Q4 Earnings Snapshot	13/03
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	13/03
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs	13/03
Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023	13/03
Sangamo Therapeutics Announces Data from Novel Proprietary Neurotropic Aav Capsid Demonstrating Industry-Leading Blood-Brain Barrier Penetration and Brain Transduction in Nhps	13/03
Sangamo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/03
Sangamo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast	12/03
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease	12/02
Sangamo Therapeutics Says Early Phase 1/2 Data Shows 'Durable' Safety, Efficacy of Fabry Disease Drug Candidate	06/02
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile	06/02
Sangamo Therapeutics, Inc. Announces Updated Preliminary Data from the Phase 1/2 STAAR Clinical Study Evaluating Isaralgagene Civaparvovec, or ST-920	05/02
Vaxcyte Names Chief People Officer	16/01
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) dropped from NASDAQ Biotechnology Index	15/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Sangamo Therapeutics, Inc.

Azioni

SGMO

US8006771062

Altre lingue

Filtri